With Dicerna's NASH Asset, Boehringer Found What It Was Looking For

02 Nov 2017

In eyeing NASH, the firms both zeroed in on the same target, considered inaccessible to traditional modalities. The deal gives BI an RNAi approach, joining its Phase II anti-inflammatory candidate for NASH.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Dicerna Pharmaceuticals Inc. and Boehringer Ingelheim GMBH have linked up to evaluate an RNA-interference approach to an undisclosed, difficult-to-drug target for non-alcoholic steatohepatitis (NASH) – one each company had been working on separately.

The transaction, which may kick-start Dicerna's new partnering strategy as it carries out a shift in R&D direction, would give...